Pardes Biosciences and FS Development II Corp (NASDAQ: FSII) Announce Union Contract

July 2, 2021

Pardes Biosciences, Inc., an early-stage biopharmaceutical corporation, and FS Development II Corp (NASDAQ: FSII), a unique purpose purchase business backed by Foresite Capital, today announced they have arrived into a conclusive merger contract.  In Conclusion of a deal new company to be called Pardes Biosciences, Inc Upon finishing the deal, the company will be retitled “Pardes Biosciences, Inc.” and led by Uri A. Lopatin, M.D., Chief Executive Officer of Pardes….